Myovant Sciences EBIT

Myovant Sciences (MYOV) currently reports a EBIT of $-150M as of December 2022. That compares with $-210M in the prior-year period — up 30.7% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Myovant Sciences's EBIT history and peer comparisons.

Myovant Sciences's EBIT increased from $-210M to $-150M — a 30.7% year-over-year increase (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Myovant Sciences's EBIT of $-150M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Myovant Sciences reported $-150M in EBIT as of December 2022. That compares with $-210M in the prior-year period — up 30.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-150M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Myovant Sciences, and consider following MYOV for alerts when major investors trade the stock.